Background: Trabectedin (T) maintenance beyond 6 cycles (cy) of treatment in responding pts with ASTS is associated with improved progression-free survival (PFS) vs T discontinuation (Le Cesne, Lancet Oncol 2015). The impact of T rechallenge after progressive disease (PD) was prospectively analyzed by the French Sarcoma Group in the national randomized phase II trial (T-DIS; NCT01303094).
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Get in touch with N.
Contact N., search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack